TABLE 1—Continued

<table>
<thead>
<tr>
<th>Application No.</th>
<th>Drug</th>
<th>Applicant</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA 086034</td>
<td>Isosorbide Dinitrate Tablets USP, 5 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 086188</td>
<td>Germaistine (ergoloid mesylates) Sublingual Tablets, 1 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 086385</td>
<td>Nandrolone Decanoate Injection, 50 mg/mL</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 086562</td>
<td>Wigraine (ergotamine tartrate and caffeine) Tablets USP, 1 mg/100 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 086742</td>
<td>Choleodyl SA (oxytriphylline) Extended-Release Tablets, 600 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 086835</td>
<td>Chlorpromazine HCl Oral Concentrate USP, 100 mg/mL</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 087233</td>
<td>Ergoloid Mesylates Sublingual Tablets USP, 0.5 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 087244</td>
<td>Ergoloid Mesylates Tablets USP, 1 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 087244</td>
<td>Tolbutamide Tablets USP, 500 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 087244</td>
<td>Aminophylline Oral Solution USP, 105 mg/5 mL (Dye Free)</td>
<td>Actavis Mid Atlantic, LLC, Subsidiary of Teva Pharmaceuticals USA, Inc.</td>
</tr>
<tr>
<td>ANDA 088128</td>
<td>Nandrolone Decanoate Injection, 200 mg/mL</td>
<td>Watson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.</td>
</tr>
<tr>
<td>ANDA 088337</td>
<td>Ergostat (ergotamine tartrate) Sublingual Tablets USP, 2 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 088477</td>
<td>Thoridazine HCl Tablets USP, 15 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 088561</td>
<td>Thoridazine HCl Tablets USP, 10 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 088564</td>
<td>Thoridazine HCl Tablets USP, 100 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 088724</td>
<td>Methylothiazide Tablets USP, 5 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 088734</td>
<td>Mecizine HCl Tablets, 25 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>ANDA 088769</td>
<td>Mepivacaine HCl Injection USP, 1%</td>
<td>Pliva, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.</td>
</tr>
<tr>
<td>ANDA 088770</td>
<td>Mepivacaine HCl Injection USP, 2%</td>
<td>Watson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.</td>
</tr>
<tr>
<td>ANDA 088827</td>
<td>Thoridazine HCl Tablets USP, 200 mg</td>
<td>Watson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.</td>
</tr>
<tr>
<td>ANDA 089026</td>
<td>Procaainamide HCl Extended-Release Tablets USP, 250 mg</td>
<td>Watson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.</td>
</tr>
<tr>
<td>ANDA 089027</td>
<td>Procaainamide HCl Extended-Release Tablets USP, 500 mg</td>
<td>Watson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.</td>
</tr>
<tr>
<td>ANDA 089530</td>
<td>Prochlorperazine Edisylate Injection USP, EQ 5 mg base/mL</td>
<td>Watson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.</td>
</tr>
</tbody>
</table>

Therefore, approval of the applications listed in table 1, and all amendments and supplements thereto, is hereby withdrawn as of February 1, 2018. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in table 1 that are in inventory on the date that this notice becomes effective (see DATES) may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.


Leslie Kux,
Associate Commissioner for Policy.

[FR Doc. 2017–23046 Filed 12–29–17; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2017–N–5715]

Watson Laboratories, Inc., and Barr Laboratories, Inc., Subsidiaries of Teva Pharmaceuticals USA, Inc.; Withdrawal of Approval of 54 Abbreviated New Drug Applications; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of October 24, 2017. The document announced the withdrawal of approval of 54 abbreviated new drug applications (ANDAs) from two applicants, effective November 24, 2017. The notice inadvertently announced the withdrawal of approval for ANDA 087296 for Chlorothalidone Tablets USP, 25 milligrams, held by Watson Laboratories, Inc., a subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044. FDA confirms that the approval of ANDA 087296 is still in effect.

FOR FURTHER INFORMATION CONTACT:
Trang Tran, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1671, Silver Spring, MD 20993–0002, 240–402–7945.

SUPPLEMENTARY INFORMATION: In FR Doc. 2017–23046, appearing on page 49214 in the Federal Register of Tuesday, October 24, 2017, the following correction is made:
1. On page 49215, in table 1, the entry for ANDA 087296 is removed.


Leslie Kux,
Associate Commissioner for Policy.

[FR Doc. 2017–22853 Filed 12–29–17; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2017–D–1846]

Labeling for Combined Hormonal Contraceptives; Draft Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled “Labeling for Combined Hormonal Contraceptives.” This draft guidance provides recommendations on information that should be included in the prescribing information for combined hormonal contraceptives (CHCs), which contain estrogen and progestin. CHC products include combined oral contraceptives (COCs), as well as non-oral products such as transdermal systems and vaginal rings. Many of the labeling recommendations in this draft guidance represent class labeling that should be included in all CHC prescribing information. The draft guidance reflects many of the modifications to prescribing information mandated by the physician labeling rule (PLR) and the pregnancy and lactation labeling rule (PLLR). General advice is provided where modifications to the prescribing information for specific products are needed.

DATES: Submit either electronic or written comments on the draft guidance by March 5, 2018 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.

ADRESSES: You may submit comments on any guidance at any time as follows:

Electronic Submissions
Submit electronic comments in the following way:
• Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.
• If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions
Submit written/paper submissions as follows:
• Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

Instructions: All submissions received must include the Docket No. FDA–2017–D–1846 for “Labeling for Combined Hormonal Contraceptives: Draft Guidance for Industry.” Received comments will be included in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday.

Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public docket, see 80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)). Submit written requests for single copies of the draft guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993–0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT:
Jennifer Dao, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 5333, Silver Spring, MD 20993–0002, 301–796–8189.

SUPPLEMENTARY INFORMATION:

I. Background
FDA is announcing the availability of a draft guidance for industry entitled “Labeling for Combined Hormonal Contraceptives.” This draft guidance provides recommendations on information that should be included in the prescribing information for CHCs, which contain estrogen and a progestin. Such products include COCs, as well as non-oral products such as transdermal systems and vaginal rings. Many of the labeling recommendations in this draft guidance represent class labeling that should be included in all CHC prescribing information. The draft guidance reflects many of the modifications to prescribing information mandated by the PLR and the PLLR. General advice is provided where modifications to the prescribing information for specific products are needed.

2 See the final rule “Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products” (71 FR 3922, January 24, 2006) (21 CFR 201.56(d)(1) and 201.57(c)(9)(i)) through (iii)); see also the guidance for industry entitled “Labeling for Human Prescription Drug and Biological Products—Implementing the PLR Content and Format Requirements” available at https://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM075082.pdf.

3 See the final rule “Content and Format of Labeling for Human Prescription Drug and Biological Products: Requirements for Pregnancy and Lactation Labeling” (79 FR 72064, December 4, 2014) (21 CFR 201.56(d) and 201.57); see also the draft guidance for industry entitled “Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products—Content and Format” available at https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM425398.pdf. When final, this guidance will represent FDA’s current thinking on this topic.
General advice is provided where modifications of the prescribing information for specific products are needed.

FDA previously issued draft guidance on the prescribing information for COCs in March 2004 and invited public comment. That draft guidance was withdrawn in July 2015. However, the development of the current draft guidance took into consideration public comments submitted to the 2004 draft guidance that were science-based and consistent with current PLR and PLR labeling regulations. This draft guidance has been broadened to incorporate the more general class of CHCs.

FDA invites comments on the content of this draft guidance. In particular, FDA seeks comments on the proposed language under section 7.1 of labeling that identifies a drug interaction with all metabolic enzyme inducers. A variety of metabolic enzyme inducers have been reported to decrease the plasma concentration of the estrogen and/or progestin components of CHCs. FDA seeks comments and data regarding specific enzyme inducers or classes of inducers (e.g., cytochrome p450 3A strong inducers) that interact with CHCs; in particular, comments are requested on whether the CHC labeling should include specific inducers or classes of inducers, or if it should remain broad and essentially cover all possible cytochrome p (CYP) enzyme inducers of any pathway and potency.

This draft guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on labeling for CHCs. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. This guidance is not subject to Executive Order 12866.

II. Paperwork Reduction Act of 1995

This draft guidance refers to previously approved collections of information that are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3520). The collections of information in 21 CFR 201.56 and 201.57 (“Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products”) are approved under OMB control number 0910–0624.

III. Electronic Access

Persons with access to the internet may obtain the draft guidance at either https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or https://www.regulations.gov/


Leslie Kux,
Associate Commissioner for Policy.

[FR Doc. 2017–28252 Filed 12–29–17; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. FDA–2014–N–2347]

Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Cosmetic Export Certificate Application Process

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions associated with export certificate applications for FDA-regulated food and cosmetic products.

DATES: Submit either electronic or written comments on the collection of information by March 5, 2018.

ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before March 5, 2018. The https://www.regulations.gov electronic filing system will accept comments until midnight Eastern Time at the end of March 5, 2018. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

• Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.

• If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions

Submit written/paper submissions as follows:

• Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

• For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

Instructions: All submissions received must include the Docket No. FDA–2014–N–2347 for “Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Cosmetic Export Certificate Application Process.” Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday.

Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your